KIT and gastrointestinal stromal tumor: In order to determine if MK-4440 will induce PDCD4 expression when combined with an RTK inhibitor with broad sensitivity against a number of secondary KIT mutations, we treated the GIST cell line panel with MK-4440, ripretinib, or the combination for 20 h at a 3:1 ratio (MK-4440:ripretinib) (Figure S2).